Ready-to-use kit enables lentivirus titer determinations during the manufacture of lentivirus vectors.
For thousands of years, medicine was a descriptive art, with treatments for disease arising from astute observation and trial and error.
As the CEO of an organisation that deals exclusively in cell therapy and gene therapy, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine alongside small molecules, biologics and devices.
In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs.